Article

FDA lifts alpha-blocker contraindication for PDE-5 inhibitor

The FDA has authorized a label change for the phosphodiesterase type-5 inhibitor tadalafil (Cialis), removing a contraindication on the use of the drug with alpha-blockers.

The FDA has authorized a label change for the phosphodiesterase type-5 inhibitor tadalafil (Cialis), removing a contraindication on the use of the drug with alpha-blockers. Tadalafil had been contraindicated for use in men taking alpha-blockers, with the exception of tamsulosin hydrochloride (Flomax). Under the label change, the contraindication has been replaced with precautionary language. Alpha-blockers include alfuzosin hydrochloride (Uroxatral), doxazosin mesylate (Cardura), terazosin hydrochloride (Hytrin), prazosin hydrochloride (Minipress), and tamsulosin.

"When Cialis is co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating treatment with Cialis, and Cialis should be initiated at the lowest recommended dose," the label states.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

© 2025 MJH Life Sciences

All rights reserved.